FDA Places PC14586, for Cancers with Mutant Protein, on Fast Track

Home / Blog / FDA Places PC14586, for Cancers with Mutant Protein, on Fast Track
FDA Places PC14586, for Cancers with Mutant Protein, on Fast Track
October 23, 2020October 23, 2020
0

The U.S. Food and Drug Administration (FDA) has granted fast track designation to PC14586 as a potential treatment of advanced cancers that harbor a specific mutation affecting the protein p53, which includes some ovarian cancers. Fast track is given to support therapies with the potential to fill a serious unmet medical need. They are eligible for benefits that include more frequent discussions with the FDA, and can be considered for accelerated approval and priority review. “While targeted therapies…

You must be logged in to read/download the full post.

The post FDA Places PC14586, for Cancers with Mutant Protein, on Fast Track appeared first on BioNewsFeeds.